Marrow Therapeutics is developing precision medicines to transform the lives of people with sickle cell disease, beta thalassemia and other severe blood diseases. We specifically target the cells affected by these diseases early in their development using validated, antibody-based therapeutics with the potential to achieve a functional cure. Our expert team has deep experience developing tissue-targeted therapeutics and is committed to delivering transformational medicines for patients.